

RESEARCH

Open Access

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Consolación Melguizo^{1,2}, Jose Prados^{1,2*}, Beatriz González³, Raul Ortiz^{1,4}, Angel Concha⁵, Pablo Juan Alvarez¹, Roberto Madeddu^{6,7}, Gloria Perazzoli¹, Jaime Antonio Oliver¹, Rodrigo López⁵, Fernando Rodríguez-Serrano^{1,2} and Antonia Aránega^{1,2}

Abstract

Background: The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O⁶-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation and protein expression of MGMT in a homogenous group of GBM patients uniformly treated with radiotherapy and TMZ. The possible connection between these GBM markers was also investigated.

Methods: Seventy-eight patients with GBM treated with radiotherapy combined with concomitant and adjuvant TMZ were analyzed for MGMT and CD133. MGMT gene promoter methylation was determined by methylation-specific polymerase chain reaction after bisulfite treatment. MGMT and CD133 expression was assessed immunohistochemically using an automatic quantification system. Overall and progression-free survival was calculated according to the Kaplan–Meier method.

Results: The MGMT gene promoter was found to be methylated in 34 patients (44.7%) and unmethylated in 42 patients (55.3%). A significant correlation was observed between MGMT promoter methylation and patients' survival. Among the unmethylated tumors, 52.4% showed low expression of MGMT and 47.6% showed high-expression. Among methylated tumors, 58.8% showed low-expression of MGMT and 41.2% showed high-expression. No correlation was found between MGMT promoter methylation and MGMT expression, or MGMT expression and survival. In contrast with recent results, CD133 expression was not a predictive marker in GBM patients. Analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation were negative.

Conclusions: Our results support the hypothesis that MGMT promoter methylation status but not MGMT expression may be a predictive biomarker in the treatment of patients with GBM. In addition, CD133 should not be used for prognostic evaluation of these patients. Future studies will be necessary to determine its clinical utility.

Keywords: Glioblastoma, Radiotherapy, Temozolomide, MGMT, Methylation, CD133

* Correspondence: jcprados@ugr.es

¹Institute of Biopathology and Regenerative Medicine (IBIMER), Granada 18100, Spain

²Department of Anatomy and Embriology, University of Granada, Granada 18012, Spain

Full list of author information is available at the end of the article

Background

Glioblastoma (GBM), the most common primary brain tumor in adults, is a rapidly progressive and fatal disease with a low median overall survival [1]. The treatment of these tumors with temozolomide (TMZ) introduces alkyl groups into DNA preventing its replication. This structural modification induces cell death. However, DNA-repair proteins, such as O⁶-alkylguanine DNA alkyltransferase (AGT), are able to remove alkyl adducts from the O⁶ position of guanine. Which is especially harmful, and the O⁴ position of thymine, restoring these DNA bases and preventing TMZ-induced cell death [2]. The DNA-repair protein AGT is encoded by the gene O⁶-Methylguanine-DNA-methyltransferase (MGMT). Determination of promoter methylation of the MGMT gene is being included as a relevant factor of the patient molecular profile [3]. Although epigenetic silencing of the MGMT gene promoter has been associated with prolonged survival in glioblastoma patients [4], there is much controversy about its use as a prognostic marker for the response of patients with newly diagnosed glioblastoma to temozolomide [5,6]. Moreover, whether any correlation exists between MGMT protein expression and promoter hypermethylation and patient outcomes has not been elucidated. Therefore, various studies using different assessments have reported different results [7-11]. These inconsistencies may be caused by intratumoral heterogeneity, different evaluation methods, and different cut-off values.

The cancer stem cell (CSC) theory postulates that tumors arise from a subpopulation of cells that are characterized by self-renewal, infinite proliferative potential, multipotency, and their ability to initiate new tumors in vivo [12]. Interestingly, CSC cells are postulated to be mediators of radio- and chemo-resistance. Tumor cells with stem-like features have been identified in glioblastoma [13]. These cells express the transmembrane glycoprotein prominin-1 (CD133) (a cell-surface marker expressed on normal human neuronal stem cell) and have the ability to initiate a tumor in vivo after xenotransplantation in mice. Few data are available on the actual prognostic impact of CD133 expression in malignant gliomas. Glioblastoma stem cells are highly resistant to conventional chemotherapy and radiotherapy [14,15] and the chemo-radioresistance of these cells may be responsible for the poor clinical outcome of these patients.

The aim of our study is to determine the prognostic significance of MGMT by analyzing both MGMT gene promoter methylation and protein expression in a homogenous series of GBM patients treated with radiotherapy and temozolomide. In addition, we evaluated the immunohistochemical expression of CD133 investigating its association with MGMT and clinical outcomes.

Methods

Tissue samples

Samples were obtained from the Anatomopathological Service of Hospital Virgen de las Nieves from Granada (Spain) and the University Hospital of Sassari (Italy), from 2001 to 2009. The Ethics Committees of both Hospitals approved the collection and use of human brain tumor tissue samples. We obtained tumor tissue samples from 78 patients with newly diagnosed GBM which was histologically confirmed and Karnofsky performance score (KPS) ≥ 60 . Patients were selected regardless of extent of surgery. All patients had been treated with concurrent chemoradiotherapy (2 Gy per fraction, once a day, five days a week, 60 Gy total dose) with concomitant TMZ (75 mg per square meter of body surface area per day for seven days a week from the first to the last day of radiotherapy) followed by adjuvant TMZ (200 mg per square meter of body surface area on days 1 to 5 given at four-weekly intervals). The patient characteristics are summarized in Table 1.

Patients age 70 years or older with newly diagnosed GBM and postoperative Karnofsky performance score (KPS) greater than 60 were eligible for this nonrandomized phase II trial

DNA extraction, bisulfite treatment and methylation-specific PCR

DNA was extracted according to standard protocols. Methylation patterns in the CpG island of MGMT were determined by chemical modification of unmethylated, but not methylated, cytosine to uracil. Methylation-specific PCR (MSP) was performed with primers specific for either modified-methylated or unmethylated DNA, as described previously [16]. DNA (2 μ g) was denatured with sodium hydroxide and modified with sodium bisulfite. DNA samples were then purified (EpiTect Bisulfite Conversion). Primer sequences for the unmethylated reaction were 5'-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3' (forward primer) and 5'-AACTCCACACTCTTCCAAAA CAAAACA-3' (reverse primer), and for the methylated reaction, they were 5'-TTTCGACGTTCTAGGTTTTC GC-3' (forward primer) and 5'-GCACTCTTCCGAAAAC GAAACG-3' (reverse primer). Amplified products of PCR were electrophoresed on 3% agarose gels, were visualized by staining with ethidium bromide, and were examined under UV illumination.

Immunohistochemistry

Antibodies for MGMT (1:50; Santa Cruz Biotechnology, Inc.) and CD133 (1:50, Abcam, Cambridge, UK) were used for immunohistochemical analysis. Immunostaining was performed using the Bond Polymer Refine Detection system (Leica Microsistemas S.L.U, Barcelona, Spain). Briefly, representative paraffin blocks were cut consecutively at a

Table 1 Patient characteristics (n = 78)

Age (years)	Mean	56
	Range	24–81
Gender	Male	42 (53.8%)
	Female	36 (46.1%)
Tumor location	Frontal	20 (25.6%)
	Parietal	13 (16.6%)
	Temporal	13 (16.6%)
	Occipital	11 (14.1%)
	More than one lobe	21 (26.9%)
Duration of symptoms prior to diagnosis	< 3 months	60 (76.9%)
	≥ 3 months	18 (23.1%)
Karnofsky performance score	≥ 60	78 (100%)

thickness of 4 mm, and immunohistochemical staining was carried out using the Microprobe Immuno/DNA stainer (Fisher Scientific, Tustin, CA, USA). Sections were deparaffinized in xylene and treated with 0.3% hydrogen peroxide in methanol for 20 min to block endogenous peroxidase activity. The sections were washed in phosphate-buffered saline and then incubated with primary antibodies for 60 min. The samples were then incubated in secondary antibody for 8 min. The substrate chromogen, 3,3'-diaminobenzidine (DAB), enabled visualization of the complex via a brown precipitate. Hematoxylin (blue) counterstaining enabled the visualization of the cell nuclei. Omission of primary antibody served as a negative control. Readings were taken automatically with the ACIS III DAKO system for quantification immunohistochemistry and were verified by two experienced pathologist. The percentage of stained tumor cells was scored as +/- (<10%), 1+ (10% to 25%), 2+ (25% to 50%), 3+ (>50%). For statistical analysis, scores of +/- and 1+ were defined as low-expression group and scores of 2+ and 3+ were defined as high-expression.

Statistical analysis

Overall survival (OS) was calculated from the date of the diagnosis. The progression-free survival (PFS) was calculated from the date of the progression, according of MacDonald criteria [17]; size and volume ≥ 25% of initial measurements, or appearance of a new lesion, or if the patient's neurologic condition worsened and required an increased dose of steroids. The PFS and OS curves were estimated by the Kaplan-Meier method and compared using the two-sided log-rank test. A multivariable analysis was done using the Cox proportional hazards regression to determine the prognostic effect of variables. Contingency tables were analyzed by χ^2 and Fisher's exact test. The McNemar test was applied to compare variables before and after treatment. All calculations were made using the statistical software SPSS,

version 15.0. Statistical significance was set at the level of $P < 0.05$.

Results

MGMT promoter methylation status and MGMT protein expression

The methylation status of the MGMT promoter and MGMT protein expression was determined for 76 of the 78 tumors (97.4%). Two of the 78 GBM cases were excluded due to unsuccessful PCR amplification. MGMT promoter methylation was detected in 44.7% (34/76) of the GBM samples analyzed by MSP (Figure 1). A positivity score of 1+, 2+ and 3+ were detected in 31 (40.8%), 19 (25%) and 15 (19.7%) cases respectively (Figure 2). Only 11 (14.5%) cases showed a score of +/- (Table 2). For the correlation of MGMT promoter methylation with MGMT protein expression, the scores +/- and 1+ were categorized into a low-expression group (42, 55.3%), and scores 2+ and 3+ into a high-expression group (34, 44.7%). Among the 42 unmethylated tumors, 22 (52.4%) showed low-expression of MGMT and 20 (47.6%) showed high-expression while among the 34 methylated tumors, 20 (58.8%) showed low-expression of MGMT and 14 (41.2%) showed high-expression. No correlation between MGMT protein expression and MGMT promoter methylation was observed ($P = 0.903$).

CD133 protein expression

CD133 expression was available for 75 of the 78 patients (96.2%). Among the 75 samples, 26 (34.7%), 27 (36%) and 7 (9.3%) were included as scores 1+, 2+ and 3+ respectively. Fifteen (20%) cases showed a score of +/- (Figure 3). As was done previously, to correlate MGMT and CD133 protein expression, the scores were categorized into a low-expression group (41, 54.7%), and a high-expression group (34, 45.3%) (Table 2). Analysis of a possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation was negative.

Influence of MGMT promoter methylation status and MGMT and CD133 protein expression on overall survival

Statistical analysis showed a significant correlation between OS and MGMT promoter methylation status (Figure 4A). The median OS among patients with methylated MGMT promoter tumors was 19 months (95% CI, 9.6–28.4 months) compared with 13 months (95% CI, 10.5–15.4 months) in patients with unmethylated MGMT promoter tumors (log-rank, $P = 0.031$). In contrast, OS showed no statistically significant differences when it was correlated with MGMT expression (log-rank, $P = 0.894$) (Figure 4B). The median OS among patients with high-expression of MGMT was 12 months (95% CI, 8.8–15.2 months) compared with 13 months




Figure 1 Representative methylation-specific PCR (MSP) analyses of the MGMT promoter in GBM tissue from eleven patients (P). Note the presence of bands in both the unmethylated (U, 93 bp) and methylated (M, 81 bp) lanes for glioblastoma samples 21, 33 and 40, reflecting a methylated MGMT promoter. The lack of a band in the lane corresponding to methylation-specific primers for GBM in the rest of the samples reflects the absence of MGMT promoter methylation. In some samples, such as sample 23, no PCR products were observed (sample excluded).

(95% CI, 8.1–17.9 months) in low-expression of MGMT tumors (log-rank, $P = 0.894$). In addition, no differences were observed between survival estimates of patients with CD133 low-expression tumors and CD133 high-expression tumors (Figure 4C). The median OS among patients with CD133 high-expression tumors was 14 months (95% CI, 9.1–18.9 months) compared with 13 months (95% CI, 6.1–19.8 months) in CD133 low-expression tumors (log-rank, $P = 0.787$).

Influence of MGMT promoter methylation status and MGMT and CD133 protein expression on progression-free survival

The median PFS was 8 months (95% CI, 4–12 months) for the methylated MGMT promoter status compared with 6 months (95% CI, 2.6–9.4 months) for the unmethylated MGMT promoter status, showing a significant correlation (log-rank, $P = 0.036$) (Figure 5A). By contrast, no significant correlation was observed between PFS and MGMT protein expression (Figure 5B). Finally, in these groups, the median PFS was 7 months (95% CI, 5.2–8.8 months) for low-CD133 expression tumors compared with 8 months (95% CI, 6.7–9.3 months) for high-CD133 expression tumors ($P = 0.118$) (Figure 5C).

Influence of MGMT promoter methylation status and MGMT and CD133 protein expression on treatment response

All patients were assessed for clinical and radiological response. The statistical analysis showed that only the MGMT promoter status significantly correlated with radiological response ($P = 0.036$). The response rate was significantly higher among patients with a methylated MGMT promoter status versus an unmethylated status (43.3% and 17.5%, respectively) ($P = 0.036$) (Table 3).

MGMT promoter methylation and MGMT and CD133 protein expression on recurrent GBM

This study included 11 patients of the 78 patients who underwent reoperation for tumor recurrence after radio-chemotherapy. One of the 11 GBM cases was excluded. In spite of the few samples, there were no significant differences between variables before and after treatment with radiotherapy and temozolomide (McNemar test) (Table 4).

Discussion

Clinical trials have demonstrated a significantly prolonged median survival of GBM patients treated with TMZ associated to radiotherapy after surgical resection [18-20]. In addition, a strong correlation between the MGMT gene promoter methylation status and the TMZ treatment effect and outcome was shown by Hegi et al. [4], confirming previous results which correlated MGMT inactivation and clinical response to alkylating agents [16,21]. Criniere et al. [22] showed that while the MGMT promoter methylation status had no impact on the OS of GBM patients treated with alkylating agents, it did have an impact on those treated with chemo-radiotherapy, suggesting that the prognostic impact of this methylation is dependent on therapeutic modalities. In fact, Weller et al. [23] analyzed patients with GBM treated with radiotherapy, with chemotherapy and with both radiotherapy and chemotherapy and showed that the methylation status was a significant prognostic factor for OS and PFS only in the subgroup of patients treated with radiotherapy and concurrent TMZ. These results have been recently confirmed by Cao et al. [8], Minniti et al. [24] and Kim et al. [25]. Recently, the methylation status was analyzed in elderly patients with GBM and was found to be strictly correlated with the pattern of, and time until, GBM recurrence [26], but not with its




Figure 2 Representative photomicrographs illustrating different percentages of MGMT-stained tumor cells scored as +/- (A, B, C and D), 1+ (E), 2+ (F, G, H and I), 3+ (J, K and L) (see Methods) (20x).

Table 2 Association of MGMT promoter methylation and MGMT and CD133 expression in human GBM

		Total	Methylated	Unmethylated	Not done
MGMT expression					
Low-expression	+/-, +	42 (55.3%)	20 (26.3%)	22 (29%)	2 (2.6%)
High-expression	++, +++	34 (44.7%)	14 (18.4%)	20 (26.3%)	
CD133 expression					
Low-expression	+/-, +	41 (54.7%)	16 (21.3%)	25 (33.4%)	3 (4%)
High-expression	++, +++	34 (45.3%)	18 (24%)	16 (21.3%)	

Data are represented as the percentage of the total of analyzed patients.

evolution after recurrence [27]. Rivera et al. [28] demonstrated that MGMT promoter methylation was a predictor of survival in GBM treated exclusively with radiotherapy. In addition, a randomized phase III trial comparing standard adjuvant TMZ with a dose-dense schedule in newly diagnosed GBM confirmed the prognostic significance of MGMT methylation in GBM [29]. However, previous studies considered promoter methylation of the MGMT gene not to be a reliable prognostic factor of responsiveness to alkylating agents in glioblastomas [30]. Recent studies have also questioned the role

of promoter methylation status of MGMT in GBM. Yachi et al. [31] failed to establish this correlation in a larger number of patients and showed that neither MSP-MGMT methylation nor immunohistochemical MGMT expression had prognostic implications in GBM patients. Similarly, Tang et al. [32] did not find a correlation between progression-free survival and MGMT promoter methylation in chinese patients. In this context, we conducted a retrospective study in a homogeneous series of patients diagnosed with GBM treated with radiotherapy and concurrent temozolomide using MSP, which has




Figure 3 Representative photomicrographs illustrating different percentages of CD133 stained tumor cells corresponding to being scored as +/- (A), 1+ (B and C), 2+ (D), 3+ (E) (see methods) (20x).





Table 3 Radiologic response of GMB patients following Macdonald et al. [17]

MGMT	Radiologic response	
	Negative	Positive
Unmethylated	33 (82.5%)	7 (17.5%)
Methylated	17 (56.7%)	13 (43.3%)
Total	50 (71.4%)	20 (28.6%)

The methylation of MGMT showed a significant correlation with radiologic response ($p < 0.05$).

been proposed as the most convenient technique in clinical routine diagnostics [33]. We found that the percentage of methylation of the MGMT promoter to be higher than that reported by Hegi et al. [4] but similar to those reported by other authors [22,34]. The MGMT methylation status was clearly confirmed as an independent prognostic factor of GBM PFS and OS. In addition, patients with a methylated MGMT promoter status had higher response rates to TMZ and radiation therapy compared to those with a non-methylated status, so that MGMT methylation was a predictive factor for radiologic response

On the other hand, the association between MGMT protein expression and promoter methylation in vivo has been widely discussed. Several studies have reported a significant association of high MGMT expression and poor prognosis of patients [7-10,35-38]. We analyzed the expression of MGMT by immunohistochemistry using a digital quantitative method to avoid observer variability [39]. Our study clearly showed no correlation between MGMT expression and MGMT promoter methylation, supporting the finding observed by Rodriguez et al. [40] and Uno et al. [41], or overall survival or radiological

Table 4 Modulation of MGMT promoter methylation

Patient	Pre-treatment			Post-treatment		
	MGMT Promoter	MGMT	CD133	MGMT Promoter	MGMT	CD133
Patient 1	M	+	++	M	+/-	+
Patient 2	M	++	+	U	++	+/-
Patient 3	U	+++	+	U	+	++
Patient 4	M	++	+	M	++	+
Patient 5	M	+	++	U	+	+
Patient 6	U	+	+	M	+	+
Patient 7	U	+	+	U	+	+++
Patient 8	M	+	++	U	+	++
Patient 9	U	+/-	+	-	-	-
Patient 10	U	+/-	+	U	++	++
Patient 11	M	++	+	M	+++	+

MGMT and CD133 in recurrent GBM before and after treatment with radiotherapy and temozolomide.

response coinciding with those findings of Preusser et al. [11]. The regulation of the MGMT gene is a complex phenomenon in which promoter hypermethylation is one of the factors that influence the final expression of the protein. In this context, the recent demonstration that there is discordance between MGMT promoter methylation and levels of MGMT mRNA expression suggests that other mechanisms may regulate the expression of this enzyme [42]. It also possibly suggests that promoter methylation and expression alone are not sufficient to provide information on the expected clinical course in patients with malignant glioma who receive chemotherapy with alkylating agents. In fact, a comprehensive study undertaken by sequencing the MGMT gene promoter has shown a strong correlation between the methylation site and treatment response [43].

CD133, a five-transmembrane cell surface protein found in human stem cells from various sources including the central nervous system [44], has been proposed to detect GBM CSCs. Considering the inherent resistance of CSCs to chemotherapy and radiotherapy [14,15], it has been hypothesized that the clinical outcome will be inversely related to the presence of CSC-marker-positive cells. However, the impact of the presence of CSC in the clinical progression of tumors is unknown. Few studies exploring the prognostic value of CD133 expression as a marker of CSC in GBM have been undertaken; most were heterogeneous and used different methods (QRT-PCR, immunohistochemistry, FACS) so that comparisons are difficult. Intense CD133 expression was detected in high-grade oligodendroglial tumors [45] and in grade II-IV gliomas [46], both with poor prognoses. Similar results were founded in grade IV gliomas where CD133 expression was related to OS and PFS [47]. Murat et al. [48] provided evidences that the glioblastoma stem cell phenotype (including CD133 expression) correlated with chemoradiotherapy resistance and patient survival. In a study with very homogeneous samples of GBM, high expression of CD133 was found to be an unfavorable prognostic factor [49]. In addition, an in vitro study using CSC obtained from 44 GBM patients to evaluate CD133/Ki67 expression by immunohistochemical analysis, concluded that CD133+ was correlated to survival [50]. However, the same authors demonstrated that high expression of CD133 was associated with a better prognosis when detected by FASScan [51]. Similar results were previously found by Joo et al. [52] who described CD133 as a favourable prognostic factor for GBM. In this context, our study clearly demonstrates that CD133 has no implication in the prognoses of GBM patients supporting similar results of Kim et al. [53]. Finally, the prognostic impacts of variations of MGMT promoter methylation or MGMT and CD133 protein expression after treatment, are

not known. A previous study determined that MGMT methylation status has no prognostic value after GBM recurrence [27]. Our preliminary study in samples obtained before and after treatment from only ten patients with recurrent GBM suggested that there are no differences between the analyzed variables although the low number of patients does not allow to obtain statistically significant conclusions.

Conclusions

Our study was designed to analyze the correlations between clinical features, MGMT status (promoter methylation and gene expression) and CD133 expression, and outcome in a set of patients uniformly treated with concomitant and adjuvant TMZ and chemo radiation. In this homogeneous series, the prognostic significance of MGMT promoter methylation has been clearly demonstrated. However, MGMT protein expression showed no correlation with MGMT promoter methylation. In addition, CD133 expression was correlated neither with the survival of patients with GBM nor with MGMT. In light of our data, together with the controversies reported in the literature, further studies are warranted to clarify whether MGMT and CD133 can discriminate between biologically distinct groups of GBM.

Abbreviations

AGT: O⁶-alkylguanine DNA alkyltransferase; CSC: Cancer stem cell; DAB: 3,3'-diaminobenzidine; GBM: Glioblastoma; MGMT: O⁶-Methylguanine-DNA-methyltransferase; OS: Overall survival; PCR: Polymerase chain reaction; PFS: Progression-free survival; TMZ: Temozolamide.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CM, JP and AA participated in the project design, coordination the experiments, and manuscript preparation. RO, JAO and FRS carried out bisulfite treatment and methylation-specific PCR. AC, PJA and RL carried out immunohistochemical analysis. BG and RM participated in the collected and analyzed the clinical data. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by the Instituto de Salud Carlos III (FIS) through Project no. PI11/01862 and by the Consejería de Salud de la Junta de Andalucía through Project no. PI-0338.

Author details

¹Institute of Biopathology and Regenerative Medicine (IBIMER), Granada 18100, Spain. ²Department of Anatomy and Embryology, University of Granada, Granada 18012, Spain. ³Service of Medical Oncology, Virgen de las Nieves Hospital, Granada 18014, Spain. ⁴Department of Health Science, University of Jaén, Jaén 23071, Spain. ⁵Anatomopathological Service, Virgen de las Nieves Hospital, Granada 18014, Spain. ⁶Department of Biomedical Science - Histology, University of Sassari, Sassari, Italy. ⁷National Institute of Biostructures and Biosystems, INBB, Sassari, Italy.

Received: 21 October 2012 Accepted: 10 December 2012
Published: 17 December 2012

References

1. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M: **Current therapeutic paradigms in glioblastoma.** *Rev Recent Clin Trials* 2010, **5**:14–27.
2. Brennan J, Margison GP: **Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene.** *Proc Natl Acad Sci USA* 1986, **83**:6292–6296.
3. Weller M, Stupp R, Reifenberger G, Brandes AA, Van den Bent MJ, Wick W, Hegi ME: **MGMT promoter methylation in malignant gliomas: ready for personalized medicine?** *Nat Rev Neurol* 2010, **6**:39–51.
4. Hegi ME, Diserens C, Gorila T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: **MGMT gene silencing and benefit from temozolomide in glioblastoma.** *N Engl J Med* 2005, **352**:997–1003.
5. Bleeker FE, Molenaar RJ, Leenstra S: **Recent advances in the molecular understanding of glioblastoma.** *J Neurooncol* 2012, **108**:11–27.
6. Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Kayama T, Shibui S: **Pathological findings and prognostic factors in recurrent glioblastomas.** *Brain Tumor Pathol* 2012. doi:10.1007/s10014-012-0084-2.
7. Nakasu S, Fukami T, Baba K, Matsuda M: **Immunohistochemical study for O⁶-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.** *J Neurooncol* 2004, **70**:333–334.
8. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ: **The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.** *Neurosurgery* 2009, **65**:866–875.
9. Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T: **Prognostic significance of the immunohistochemical expression of O⁶-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.** *Neuropathology* 2009, **29**:379–388.
10. Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T: **O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.** *Int J Clin Oncol* 2010, **15**:352–358.
11. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M: **Anti-O⁶-methylguanine methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.** *Brain Pathol* 2008, **18**:520–532.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL: **Stem cells, cancer, and cancer stem cells.** *Nature* 2001, **414**:105–111.
13. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: **Identification of a cancer stem cell in human brain tumors.** *Cancer Res* 2003, **63**:5821–5828.
14. Liu L, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: **Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.** *Mol Cell Oncol* 2006, **5**:67–78.
15. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: **Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.** *Nature* 2006, **444**:756–760.
16. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: **Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.** *N Engl J Med* 2000, **343**:1350–1354.
17. Macdonald DR, Cascino TL, Schold SC, Cairncross JG: **Response criteria for phase II studies of supratentorial malignant glioma.** *J Clin Oncol* 1990, **8**:1277–1280.
18. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: **Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.** *N Engl J Med* 2005, **352**:987–996.
19. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W: **Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.** *J Clin Oncol* 2006, **24**:2707–2714.

20. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: **Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.** *Lancet Oncol* 2009, **10**:459–466.
21. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Céspedes M, Garcia-Villanueva M, Arribas L, Esteller M: **CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.** *Clin Cancer Res* 2004, **10**:4933–4938.
22. Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M: **MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.** *J Neurooncol* 2007, **83**:173–179.
23. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Ninkkav G, Pietsch T, Wiestler O, Reifenberger G, Von Deimling A, Loeffler M: **Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.** *J Clin Oncol* 2009, **27**:5743–5750.
24. Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrico R, Giangaspero F: **Correlation between O⁶-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.** *J Neurooncol* 2011, **102**:311–316.
25. Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO: **MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.** *Int J Radiat Oncol Biol Phys* 2012. doi:10.1016/j.ijrobp.2011.12.086.
26. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, Morandi L, Spagnoli F, Ermani M: **Recurrence pattern alter temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status.** *J Clin Oncol* 2009, **27**:1275–1279.
27. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M: **O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.** *Neuro Oncol* 2010, **12**:283–288.
28. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD: **MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.** *Neuro Oncol* 2010, **12**:116–121.
29. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP: **RT0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract].** *J Clin Oncol* 2011, **29**, suppl; abstr 2006.
30. Blanc JL, Wager M, Guillhot J, Kusy S, Bataille B, Chanterreau T, Lapierre F, Larsen CJ, Karayan-Tapon L: **Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.** *J Neurooncol* 2004, **68**:275–283.
31. Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, Katayama Y, Nagase H: **Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.** *Int J Oncol* 2008, **33**:469–475.
32. Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T: **Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.** *Med Oncol* 2012, **29**:1292–1296.
33. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M: **Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.** *PLoS One* 2012, **7**:e33449.
34. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C: **Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.** *Br J Cancer* 2009, **101**:124–131.
35. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D: **Correlation between O⁶-methylguanine-DNA methyltransferase expression and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.** *J Clin Oncol* 2007, **25**:1470–1475.
36. Nakasu S, Fukami T, Jito J, Matsuda M: **Prognostic significance of loss of O⁶-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.** *Surg Neurol* 2007, **68**:603–608.
37. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J: **Pitfalls in the assessment of MGMT expression and its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.** *Acta Neuropathol* 2008, **115**:249–259.
38. Watanabe R, Nakasu Y, Tashiro H, Mitsuya K, Ito I, Nakasu S, Nakajima T: **O⁶-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.** *Brain Tumor Pathol* 2011, **28**:127–135.
39. Arazi Y, Mizoguchi M, Yoshimoto K, Shono T, Amano T, Nakamizo A, Suzuki SO, Iwaki T, Sasaki T: **Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.** *Brain Tumor Pathol* 2011, **28**:25–31.
40. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, James CD, Passe S, Slezak J, Giannini C: **MGMT immunohistochemical expression and promoter methylation in human glioblastoma.** *Appl Immunohistochem Mol Morphol* 2008, **16**:59–65.
41. Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK: **Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.** *Clinics* 2011, **66**:1747–1755.
42. Kreth S, Thon N, Eigenbrog S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW: **O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.** *PLoS One* 2011, **18**:e17156.
43. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, Rostad S, Foltz G: **Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.** *PLoS One* 2011, **6**:e16146.
44. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL: **Direct isolation of human central nervous system stem cells.** *Proc Natl Acad Sci USA* 2000, **97**:14720–14725.
45. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP: **CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.** *Brain Pathol* 2008, **18**:370–377.
46. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J: **Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.** *J Exp Clin Cancer Res* 2008, **27**:85–92.
47. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC: **Stem cell marker CD133 affects clinical outcome in glioma patients.** *Clin Cancer Res* 2008, **14**:123–129.
48. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME: **Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.** *J Clin Oncol* 2008, **26**:3015–3024.
49. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D: **Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.** *Ann Surg Oncol* 2011, **18**:2937–2945.
50. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R: **Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.** *Clin Cancer Res* 2008, **14**:8205–8212.

51. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM: **Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.** *Cancer* 2011, **117**:162–174.
52. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH: **Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastoma.** *Lab Invest* 2008, **88**:808–815.
53. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, Lee MC: **The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.** *Neuropathology* 2011, **31**:494–502.

doi:10.1186/1479-5876-10-250

Cite this article as: Melguizo *et al.*: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. *Journal of Translational Medicine* 2012 **10**:250.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

